About Us

Sensifree is a medical device company, on a mission to revolutionize how patients are cared for in hospitals and at home.

We are developing continuous & noninvasive hemodynamic monitoring solutions, based on our proprietary platform.

Our first product provides continuous blood pressure monitoring for patients going through procedures in the OR or admitted to the ICU, where they are typically hemodynamically unstable. Our solution enables immediate intervention based on real time and accurate data in order to avoid potentially fatal complications.

Our roadmap further includes expansion into other hospital units, remote monitoring of chronically ill and discharged patients, as well as hypertension diagnosis and management.

About Us

Sensifree is a medical device company, on a mission to revolutionize how patients are cared for in hospitals and at home.

We are developing continuous & noninvasive hemodynamic monitoring solutions, based on our proprietary platform.

Our first product provides continuous blood pressure monitoring for patients going through procedures in the OR or admitted to the ICU, where they are typically hemodynamically unstable. Our solution enables immediate intervention based on real time and accurate data in order to avoid potentially fatal complications.

Our roadmap further includes expansion into other hospital units, remote monitoring of chronically ill and discharged patients, as well as hypertension diagnosis and management.

Blood Pressure Monitoring Redefined

One of the most pressing areas in which continuous blood pressure monitoring is needed is in critical care settings (operating rooms and intensive care units).

Recent studies show associations between episodes of intraoperative hypotension (low blood pressure) and increased risk of acute kidney injury (AKI) and myocardial injury (MI) – the leading cause of 30 days post-operative mortality.

The current gold standard, arterial line, is used only in small percentage of the cases. Although it is continuous, it is invasive and expensive.

Thus, in the majority of procedures, blood pressure is monitored using a cuff, providing only intermittent readings.

Hypotension episodes occurring between these readings might go unknown to anesthesiologists, therefore potentially delaying needed intervention. Blood pressure is a critical vital sign that can be regulated using drugs or fluids. This makes continuous blood pressure monitoring essential for timely identification and management of hypotension episodes, in order to minimize the risk of MI and AKI.

Our first product is a noninvasive and continuous blood pressure monitoring device, enabling arterial line grade monitoring for extended patient populations at low cost.

In addition to blood pressure values (Mean Arterial Pressure (MAP), Systolic and Diastolic), our product also provides a measure of Pulse Pressure Variability (PPV), a key indicator for perioperative goal directed fluid therapy.

The device is risk-free, requiring a simple set up by a nurse or technician. It consists of a disposable sensor, BP module and an optional bedside monitor.

One of the most pressing areas in which continuous blood pressure monitoring is needed is in critical care settings (operating rooms and intensive care units).

Recent studies show associations between episodes of intraoperative hypotension (low blood pressure) and increased risk of acute kidney injury (AKI) and myocardial injury (MI) – the leading cause of 30 days post-operative mortality.

The current gold standard, arterial line, is used only in small percentage of the cases. Although it is continuous, it is invasive and expensive.

Thus, in the majority of procedures, blood pressure is monitored using a cuff, providing only intermittent readings.

Hypotension episodes occurring between these readings might go unknown to anesthesiologists, therefore potentially delaying needed intervention. Blood pressure is a critical vital sign that can be regulated using drugs or fluids. This makes continuous blood pressure monitoring essential for timely identification and management of hypotension episodes, in order to minimize the risk of MI and AKI.

Our first product is a noninvasive and continuous blood pressure monitoring device, enabling arterial line grade monitoring for extended patient populations at low cost.

In addition to blood pressure values (Mean Arterial Pressure (MAP), Systolic and Diastolic), our product also provides a measure of Pulse Pressure Variability (PPV), a key indicator for perioperative goal directed fluid therapy.

The device is risk-free, requiring a simple set up by a nurse or technician. It consists of a disposable sensor, BP module and an optional bedside monitor.

Relationship Between Intraoperative Hypertension and Clinical Outcomes

85%
85% of patients are monitored using intermittent cuff measurements intraoperatively, that lead to missing hypotension events
1min
Even accumulation of short durations (<1 minute) of hypotension, defined as MAP<55 mmHg, are associated with costly acute kidney injury (7.4% of cases) and myocardial injury (2.3% of cases)
$1,460
On average, those complications cost $1,460 per procedure.
By using our highly cost effective device, healthcare systems’ expenditure will be greatly reduced

Sensifree’s Platform Technology

Our proprietary, patent pending technology platform comprises of two main elements:

1. Unique PPG based optical sensor technology
2. Advanced algorithmic layer to calculate and track blood pressure

Our sensor features red and infra-red wavelengths that track blood volume inside the pulsating blood vessel and then constructing a unique signal, originating at the index finger. The result is a continuous waveform that is proportional to the arterial pressure wave.

We then apply our proprietary algorithms, based on biomechanical modeling of the cardiovascular system to extract and track systolic and diastolic blood pressures, as well as mean arterial pressure (MAP).

SensifreePuzzel3
Key benefits of our Platform:

 

  • Noninvasive & Continuous waveform trace display
  • Real time monitoring and tracking of blood pressure values
    (MAP, systolic and diastolic)
  • Early detection and alert of condition deterioration
  • Based on analytic cardiovascular model, not relying
    on heuristic parameters database
  • Simple sensor positioning
  • Affordable and reliable design
 

Our proprietary, patent pending technology platform comprises of two main elements:

  1. Unique PPG based optical sensor technology
  2. Advanced algorithmic layer to calculate and track blood pressure

Our sensor features red and infra-red wavelengths that track blood volume inside the pulsating blood vessel and then constructing a unique signal, originating at the index finger. The result is a continuous waveform that is proportional to the arterial pressure wave.

We then apply our proprietary algorithms, based on biomechanical modeling of the cardiovascular system to extract and track systolic and diastolic blood pressures, as well as mean arterial pressure (MAP).

Key benefits of our Platform:

 

  • Noninvasive & Continuous waveform trace display
  • Real time monitoring and tracking of blood pressure values
    (MAP, systolic and diastolic)
  • Early detection and alert of condition deterioration
  • Based on analytic cardiovascular model, not relying
    on heuristic parameters database
  • Simple sensor positioning
  • Affordable and reliable design

Sensifree’s Platform Breadth of Parameters

Blood Pressure (BP) &
Mean Arterial Pressure (MAP)
Heart Rate (HR) &
Heart Rate Variability (HRV)
Cardiac Output (CO)
Respiration Rate (RR)
Vascular Resistance
Pulse Pressure (PP) &
Pulse Pressure Variability (PPV)
Stroke Volume (SV) &
Stroke Volume Variability (SVV)
Blood Pressure (BP) &
Mean Arterial Pressure (MAP)
Heart Rate (HR) &
Heart Rate Variability (HRV)
Cardiac Output (CO)
Respiration Rate (RR)
Vascular Resistance
Pulse Pressure (PP) &
Pulse Pressure Variability (PPV)
Stroke Volume (SV) &
Stroke Volume Variability (SVV)

Clinically Validated Sensor Technology

We analyzed data from more than 250 patients with over 1.6 million data points with reference to arterial line, the gold standard.

The comparison demonstrated that our accuracy results are within the FDA requirements for blood pressure monitors, according to the ISO81060-2 standard.

News

Jul 10

2018
N_America_Winner1

Cupertino, Calif. (July 10, 2018) – Sensifree, a medical device company developing advanced RF-based hemodynamic monitoring solutions, announces that it has been chosen from thousands of entrants as a winner of the Red Herring Top 100 North America 2018 award.  The award recognizes Sensifree as among this year’s most exciting and innovative private technology companies in the North American business region.

“We are honored to be a Red Herring Top 100 winner, which is an important acknowledgment of our innovative solution to continuous blood pressure monitoring without the need for an invasive arterial line,” said Eran Agmon, Sensifree’s co-founder and CEO. “We are well positioned to accelerate development of our first product, a blood pressure monitoring solution for critical care settings, and advance this product toward commercialization.”

Companies considered for the 2018 Red Herring Top North American award were judged by industry experts, insiders and journalists on a wide variety of criteria including financial performance, innovation, business strategy and market penetration.

Red Herring’s editors have been evaluating the world’s startups and tech companies for over two decades.  It gives them the ability to see through the industry’s hype, to pick firms that will continue on a trajectory to success.  Brands such as Alibaba, Google, Kakao, Skype, Spotify, Twitter and YouTube have all been singled out in Red Herring’s storied history.

“2018’s crop of Top 100 winners has been among our most intriguing yet,” said Red Herring chairman Alex Vieux.  “North America has led the way in tech for so many years, and to see such unique, pioneering entrepreneurs and companies here in California, which is in many ways the heartland of the industry, has been a thrilling experience.

“What has excited me most is to see so many people forging niches in high-tech and cutting-edge sectors,” added Vieux. “Some of the technical wizardry and first-rate business models on show here at the conference has been fantastic to learn about.  We believe Sensifree embodies the drive, skill and passion on which tech thrives. Sensifree should be proud of its achievement: the competition was incredibly strong.”

Jun 14

2018
RHF100

Cupertino, Calif. (June 14, 2018) – Sensifree, a medical device company developing advanced RF-based hemodynamic monitoring solutions, announced today it has been selected as a finalist for Red Herring’s Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region.

The Red Herring editorial team selected the most innovative companies from a pool of hundreds from across North America. The nominees are evaluated on 20 main quantitative and qualitative criterion, which include disruptive impact, market footprint, proof of concept, financial performance, technology innovation, social value, quality of management, execution of strategy, and integration into their respective industries.

This unique assessment of potential is complemented by a review of the track record and standing of a company, which allows Red Herring to see past the “buzz” and make the list a valuable instrument for discovering and advocating the greatest business opportunities in the industry.

“This year was rewarding, beyond all expectations” said Alex Vieux, publisher and CEO of Red Herring. “There are many great companies generating really innovative and disruptive products in North America. We had a very difficult time narrowing the pool and selecting the finalists. Sensifree shows great promise and therefore deserves to be among the finalists. Now we’re faced with the difficult task of selecting the Top 100 winners of Red Herring North America. We know that the 2018 crop will grow into some amazing companies that are sure to make an impact.”

Finalists for the 2018 edition of the Red Herring 100 North America award are selected based upon their technological innovation, management strength, market size, investor record, customer acquisition, and financial health. During the months leading up to the announcement, Red Herring reviewed over 1200 companies in the telecommunications, security, cloud, software, hardware, biotech, mobile and other industries that completed their submissions to qualify for the award.

Sensifree’s CEO, Eran Agmon, will present at the Red Herring North America Forum in Marina Del Rey, June 18-20, 2018. The Top 100 winners will be announced at a special awards ceremony on the evening of June 20 at the event.

Jan 05

2018

Cupertino, Calif. – (BUSINESS WIRE) – Sensifree, a medical device company developing advanced RF-based hemodynamic monitoring solutions, announces results of a clinical study showing excellent concordance between the signal morphology of its RF based sensor and invasive arterial line, the standard of care for continuous blood pressure monitoring. Clinical data from the study further validate blood pressure extraction and tracking algorithms. Preliminary results demonstrate accurate tracking of systolic and diastolic pressure values.

Jan 23

2017

Neuchâtel (CH), Cupertino, CA (US), and Petach-Tikva (IL); January 23, 2017—Sensifree and CSEM join forces to create a disruptive technology for monitoring blood pressure without using a cuff. Combining CSEM’s expertise in the field of blood pressure monitoring and Sensifree’s novel, RF-based approach will pave the way for the production of a new tool for the highly attractive health wearables market.

Sep 20

2016

Sensifree Ltd. (Cupertino, Calif.) was founded in 2012 and claims to have developed a contact free, electromagnetic sensor that accurately collect a range of continuous biometric data without the need to touch the human body. The Sensifree technology uses RF signal to sense movement in the radial artery wall to track heart rate, and in the future blood pressure. Having taken the pulse digital signal processing is used to extract more information.

May 24

2016
Sensifree Secures $5M in Series A Financing Led by TransLink Capital 

Cupertino, CA and Petach-Tikva, Israel, May 24, 2016 — Sensifree, the pioneer in low power, contact free, electromagnetic sensors that accurately collect a range of continuous biometric data without the need to touch the human body, today announced it has completed a $5.0 million Series A round of financing. TransLink Capital led the investment round with participation from existing and new investors, including UMC Capital, a subsidiary of United Microelectronics Corp. (NYSE: UMC) and an undisclosed strategic investor.

Meet The Team

Eran Agmon | CEO & Co-founder

Eran is a veteran of the technology industry, with over 20 years of experience in various companies, both mature and startups, in which he held executive and senior level positions in corporate development, product strategy and marketing.
Eran brings with him proven experience in developing new businesses from scratch, with strong multi disciplinary technical background. Eran holds a B.Sc.EE degree from the Tel-Aviv University. Prior to founding Sensifree, Eran worked at Gilat Satellite Networks, Camero-Tech and Raysat Antenna Systems.

llan Barak | CTO & Co-founder

Ilan is an expert in microwaves, RF and chip design. With over 35 years of experience in the Israeli hi-tech industry and more than 20 patents filed by him, Ilan leads the technological innovation in Sensifree.
Ilan holds B.Sc. and M.Sc. degrees in electrical engineering, both from the Tel-Aviv University. Prior to founding Sensifree, Ilan worked at Gilat Satellite Networks, Intel and Raysat Antenna Systems.

Moshe Kamar, MD | CMO

Dr. Kamar is a board certified practicing general surgeon, with vast hands on experience in clinical and medical affairs, designing and overseeing multiple large scale clinical trials and FDA submissions.
Dr. Kamar also worked for Ornim Medical, Omrix Biopharmaceuticals, Johnson and Johnson and Teva Pharmaceuticals.

Asaf Bar | VP, BD & Marketing

Asaf has over 16 years of business development, marketing and finance senior level roles in medical devices and biopharma companies.
His experience includes strategic planning and execution, product development and launch and crafting partnerships.
Asaf worked also for Johnson and Johnson, Omrix Biopharmaceuticals, Lumenis and PolyPid.

Benny Zeevi, MD | Managing General Partner, Tel Aviv Venture Partners

Dr. Benny Zeevi is an interventional pediatric cardiologist and leads the fund life science investments. He is a prominent figure and deeply involved in the Israeli life sciences and digital health industries. Dr. Zeevi is the chairman of the board of several companies and advisor to other companies. Dr. Zeevi holds an MD degree (Magna Cum Laude) from the Sackler School of Medicine, Tel Aviv University, Israel.

Eric Hsia | Venture Partner, Translink Capital

Eric leads TransLink’s activities supporting portfolio companies with their customers and partners, primarily in Greater China. He is interested in companies at the intersection of health and information technology, finance and technology, and consumer services. Eric is a founder of Eternal Capital and a private investor, board member, and advisor to public and private technology companies. He earned a B.A. in Economics from Harvard College.

Eran Agmon | CEO & Co-founder

Eran is a veteran of the technology industry, with over 20 years of experience in various companies, both mature and startups, in which he held executive and senior level positions in corporate development, product strategy and marketing. Eran brings with him proven experience in developing new businesses from scratch, with strong multi disciplinary technical background. Eran holds a B.Sc.EE degree from the Tel-Aviv University. Prior to founding Sensifree, Eran worked at Gilat Satellite Networks, Camero-Tech and Raysat Antenna Systems.

llan Barak | CTO & Co-founder

Ilan is an expert in microwaves, RF and chip design. With over 35 years of experience in the Israeli hi-tech industry and more than 20 patents filed by him, Ilan leads the technological innovation in Sensifree. Ilan holds B.Sc. and M.Sc. degrees in electrical engineering, both from the Tel-Aviv University. Prior to founding Sensifree, Ilan worked at Gilat Satellite Networks, Intel and Raysat Antenna Systems.

James Welch | Regulatory & QA Advisor

James has 45 years of experience in the clinical application, development and regulatory approvals of non-invasive vital signs measurements, including blood pressure monitoring devices, while he held executive positions at Protocol Systems, Welch Allyn, Masimo, and Sotera Wireless. He is an expert in product development, quality systems and regulatory affairs.

Daniel Sessler, MD | Medical Advisor

Dr. Sessler is the Michael Cudahy Professor and Chair of the Department of OUTCOMES RESEARCH at the Cleveland Clinic. He is also Director of the OUTCOMES RESEARCH CONSORTIUM: the Consortium is the world’s largest clinical anesthesia research group and publishes a full paper every 3 days. He is an editor for Anesthesiology and serves as a reviewer for more than 50 journals. His grants total $50 million. Dr. Sessler has published more than 700 full research papers which have been cited more than 30,000 times — making him the world’s most published anesthesiologist. His awards include a Fulbright Fellowship and the ASA Excellence in Research prize.

Arthur Wallace, MD | Medical Advisor

Dr. Wallace is a professor and vice-chair of anesthesiology and perioperative care at the University of California, San Francisco and Chief of the Anesthesia Service at the Veterans Affairs Medical Center in San Francisco. He completed a B.S. in engineering and applied science with a specialty in electrical engineering at Yale. He then completed an M.D. and Ph.D. at Johns Hopkins Medical School with his Ph.D. in biomedical engineering with research in systems physiology and autonomic control of the vasculature.

Contact Us

Headquarters
21631 Stevens Creek Blvd. Suite B,
Cupertino, CA 95014, USA
Tel: +1-669-230-5116

R&D Center
4 Hamefalsim St.,
Petah Tikva 4951415, Israel
Tel: +972-3-559-8990